This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?
by Zacks Equity Research
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
by Zacks Equity Research
NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.
Novavax (NVAX) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Moderna Secures FDA Nod for Next-Gen COVID-19 Vaccine mNexspike
by Zacks Equity Research
MRNA wins FDA approval for mNexspike, a fridge-stable COVID shot, but with a narrower use label than it sought.
Here's Why Novavax (NVAX) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MRNA Seeks FDA Nod for Updated COVID-19 Vaccine
by Zacks Equity Research
Moderna files with FDA for updated Spikevax aimed at the LP.8.1 variant, which makes up 70% of U.S. COVID-19 cases.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
by Ekta Bagri
BMRN and NVAX are in the spotlight this week following announcement agreement and regulatory update.
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
by Zacks Equity Research
Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.
Company News for May 20, 2025
by Zacks Equity Research
Companies In The News Are: NVAX, REGN, RYAAY, ZIM.
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine
by Zacks Equity Research
The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up
by Zacks Equity Research
Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.
Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of 312.68% and 215.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Niagen Bioscience (NAGE) delivered earnings and revenue surprises of 100% and 13.10%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
ANIP's first-quarter 2025 revenues are likely to have been driven by increased sales of its lead product, Cortrophin Gel, and other rare disease products.
Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock?
by Zacks Equity Research
PRGO's first-quarter top line is likely to have been impacted by exited businesses and product lines, and unfavorable currency movements.
Novavax to Report First-Quarter Earnings: Is a Beat in Store?
by Zacks Equity Research
On NVAX's first-quarter earnings call, investors will likely focus on pipeline updates.
Novavax (NVAX) Flat As Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, Novavax (NVAX) closed at $6.41, indicating no shift from the previous trading day.
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS' higher companion animal product sales are likely to have driven revenues in first-quarter 2025 in both the United States and International segments.
Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter 2025 earnings release, given the absence of a marketed product.